Literature DB >> 16775613

The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.

P Sidon, H El Housni, B Dessars, P Heimann.   

Abstract

Mesh：

Year:  2006        PMID： 16775613     DOI： 10.1038/sj.leu.2404292

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  35 in total

1.  High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.

Authors:  Inmaculada Rapado; Silvia Grande; Enriqueta Albizua; Rosa Ayala; José-Angel Hernández; Miguel Gallardo; Florinda Gilsanz; Joaquin Martinez-Lopez
Journal:  J Mol Diagn       Date:  2009-03       Impact factor: 5.568

2.  Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Authors:  Jason D Merker; Carol D Jones; Stephen T Oh; Iris Schrijver; Jason Gotlib; James L Zehnder
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

3.  Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

Authors:  Todd S Laughlin; Alison R Moliterno; Brady L Stein; Paul G Rothberg
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

4.  Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.

Authors:  Cornelis J J Huijsmans; Jeroen Poodt; Paul H M Savelkoul; Mirjam H A Hermans
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

5.  JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.

Authors:  Camilla Nielsen; Stig E Bojesen; Børge G Nordestgaard; Klaus F Kofoed; Henrik S Birgens
Journal:  Haematologica       Date:  2014-06-06       Impact factor: 9.941

6.  The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.

Authors:  Camilla Nielsen; Henrik S Birgens; Børge G Nordestgaard; Lasse Kjaer; Stig E Bojesen
Journal:  Haematologica       Date:  2010-12-15       Impact factor: 9.941

7.  Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Qiaofang Chen; Pin Lu; Amy V Jones; Nicholas C P Cross; Richard T Silver; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

8.  Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.

Authors:  François W Paradis; Raynald Simard; Daniel Gaudet
Journal:  BMC Med Genet       Date:  2010-04-01       Impact factor: 2.103

9.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Authors:  David A Hinds; Kimberly E Barnholt; Ruben A Mesa; Amy K Kiefer; Chuong B Do; Nicholas Eriksson; Joanna L Mountain; Uta Francke; Joyce Y Tung; Huong Marie Nguyen; Haiyu Zhang; Linda Gojenola; James L Zehnder; Jason Gotlib
Journal:  Blood       Date:  2016-06-30       Impact factor: 22.113

10.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.